These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6361702)

  • 1. Evaluation of new indomethacin dosage forms.
    Waller ES
    Pharmacotherapy; 1983; 3(6):324-33. PubMed ID: 6361702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic overview of indomethacin and sustained-release indomethacin.
    Yeh KC
    Am J Med; 1985 Oct; 79(4C):3-12. PubMed ID: 3904441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of single-unit commercial immediate-and sustained-release capsules compared with multiple-unit polystyrene microparticles dosage forms of indomethacin.
    Tamilvanan S; Sa B
    PDA J Pharm Sci Technol; 2008; 62(3):177-90. PubMed ID: 18661867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceutical evaluation of 'Osmosin'.
    Rogers JD
    Curr Med Res Opin; 1983; 8 Suppl 2():38-54. PubMed ID: 6851625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerance of a novel precision-dose formulation of indomethacin: double-blind trials in rheumatoid arthritis and osteoarthritis.
    Bobrove AM; Calin A
    Curr Med Res Opin; 1983; 8 Suppl 2():55-61. PubMed ID: 6342962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation.
    Skinhøj A; Bechgaard H; Chasseaud LF; Brodie RR; Sharman JM; Taylor T; Hunter JO
    Int J Clin Pharmacol Ther Toxicol; 1984 Oct; 22(10):557-61. PubMed ID: 6511132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of indomethacin from a modified release system containing indomethacin as the lysine salt.
    Marzo A; Reiner A; Arrigoni Martelli E; Conte U; Colombo P; La Manna A
    Eur J Clin Pharmacol; 1987; 32(1):85-7. PubMed ID: 3108010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides.
    Vial-Bernasconi AC; Buri P; Doelker E; Beyssac E; Duchaix G; Aiache JM
    Pharm Acta Helv; 1995 Dec; 70(4):307-13. PubMed ID: 8765697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physicochemical characteristics and bioavailability of indomethacin from beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxypropyl-beta-cyclodextrin complexes.
    Jambhekar S; Casella R; Maher T
    Int J Pharm; 2004 Feb; 270(1-2):149-66. PubMed ID: 14726131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of osmotically controlled indomethacin delivery systems after repeated dosing.
    Bayne W; Place V; Theeuwes F; Rogers JD; Lee RB; Davies RO; Kwan KC
    Clin Pharmacol Ther; 1982 Aug; 32(2):270-6. PubMed ID: 7094513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the in vitro dissolution behaviour of various indomethacin formulations with their in vivo bioavailability.
    Rowe JS; Carless JE
    J Pharm Pharmacol; 1981 Sep; 33(9):561-4. PubMed ID: 6117632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.
    Adams KR; Halliday LD; Sibeon RG; Baber N; Littler T; Orme ML
    Br J Clin Pharmacol; 1982 Aug; 14(2):286-9. PubMed ID: 7104182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on the bioavailability of sustained-release indomethacin capsules].
    Li D; Yang XY; Wang JP; Wang YM; Shan J; Zhang HL; Bai YZ; Tao XH; Mo SY
    Yao Xue Xue Bao; 1985 May; 20(5):387-91. PubMed ID: 4083026
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of sustained release on the pharmacokinetic profile of indomethacin in man.
    Yeh KC; Berger ET; Breault GO; Lei BW; McMahon FG
    Biopharm Drug Dispos; 1982; 3(3):219-30. PubMed ID: 7139063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indomethacin sustained-release?
    Green JA
    Drug Intell Clin Pharm; 1984 Dec; 18(12):1004-7. PubMed ID: 6391883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind trial comparing indomethacin sustained release capsules (Indocid-R) with indomethacin capsules in patients with rheumatoid arthritis.
    Rhymer AR; Hart CB; Daurio C
    Rheumatol Rehabil; 1982 May; 21(2):101-6. PubMed ID: 7043710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis.
    Kaarela K; Lehtinen K; Mäkisara P; Holttinen K; Lamminsivu U; Gordin A
    Eur J Clin Pharmacol; 1982 Oct; 23(4):349-51. PubMed ID: 7173304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of indomethacin from two multiple-units controlled-release formulations.
    Bechgaard H; Brodie RR; Chasseaud LF; Houmøller P; Hunter JO; Siklos P; Taylor T
    Eur J Clin Pharmacol; 1982; 21(6):511-5. PubMed ID: 7075656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tramadol sustained-release capsules.
    Keating GM
    Drugs; 2006; 66(2):223-30. PubMed ID: 16451094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric acidity-dependent bioavailability of commercial sustained release preparations of indomethacin, evaluated by gastric acidity-controlled beagle dogs.
    Yamada I; Goda T; Kawata M; Shiotuki T; Ogawa K
    Chem Pharm Bull (Tokyo); 1990 Nov; 38(11):3112-5. PubMed ID: 2085896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.